Rockne Wendy Y, Grigorian Areg, Christian Ashton, Nahmias Jeffry, Lekawa Michael, Dolich Matthew, Chin Theresa, Schubl Sebastian D
University of California, Irvine, Department of Surgery, Division of Trauma, Burns and Surgical Critical Care, Orange, CA, USA.
Am J Surg. 2021 May;221(5):1076-1081. doi: 10.1016/j.amjsurg.2020.09.033. Epub 2020 Sep 26.
A comparison of outcomes between Level I (LI) and Level II (LII) Trauma Centers (TCs) performing surgical stabilization of rib fracture (SSRF) has not been well described. We sought to compare risk of mortality for patients undergoing SSRF between LI and LII TCs.
The Trauma Quality Improvement Program was queried for patients presenting with rib fracture to LI or LII TCs from 2010 to 2015. A multivariable logistic regression analysis was performed.
14,046 (7.1%) of 199,020 patients with rib fractures underwent SSRF. SSRF increased from 1304 in 2010 to 3489 in 2015: a geometric mean annual increase of 22%. LI TCs demonstrated a mortality incidence of 1.6% while LII TCs demonstrated a mortality incidence of 1.5% (p > 0.05). There was no statistically significant difference in risk of mortality after SSRF between LI and LII TCs (odds ratio 1.12, confidence interval 0.79-1.59, p-value 0.529).
Patients undergoing SSRF at LI and LII TCs have no significant difference in risk of mortality. Additionally, there is an annually growing trend across all centers in SSRF performed both for flail and non-flail segments.
关于一级(LI)和二级(LII)创伤中心(TCs)进行肋骨骨折手术固定(SSRF)的结果比较,目前尚无充分描述。我们试图比较LI和LII创伤中心接受SSRF患者的死亡风险。
查询创伤质量改进项目,以获取2010年至2015年期间因肋骨骨折到LI或LII创伤中心就诊的患者信息。进行多变量逻辑回归分析。
199,020例肋骨骨折患者中有14,046例(7.1%)接受了SSRF。SSRF从2010年的1304例增加到2015年的3489例:几何平均年增长率为22%。LI创伤中心的死亡率为1.6%,而LII创伤中心的死亡率为1.5%(p>0.05)。LI和LII创伤中心在SSRF后死亡风险方面无统计学显著差异(优势比1.12,置信区间0.79 - 1.59,p值0.529)。
在LI和LII创伤中心接受SSRF的患者在死亡风险方面无显著差异。此外,所有中心对于连枷胸和非连枷胸节段进行的SSRF均呈逐年增长趋势。